Testicular cancer survivorship: Long-term toxicity and management

Shrem, Noa Shani; Wood, Lori; Hamilton, Robert J.; Kuhathaas, Kopika; Czaykowski, Piotr; Roberts, Matthew; Matthew, Andrew; Izard, Jason; Chung, Peter; Nappi, Lucia; Jones, Jennifer; Soulières, Denis; Aprikian, Armen; Power, Nicholas; Canil, Christina

doi:10.5489/cuaj.8009

Cited by 12 publications

(6 citation statements)

References 176 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…39 With an overall survival rate at 10 years approximating 95%, 40 there has been an increasing realization that patients diagnosed and treated with GCT using a host of treatment modalities including systemic chemotherapy, radiotherapy, surgery, or a combination of these remain at risk of developing a number of clinical conditions including (but not solely confined to) anxiety, cardiovascular disease, cognitive impairment, chronic fatigue, depression, metabolic syndromes including hypogonadism, nephrotoxicity, neurotoxicity, infertility, ototoxicity, and importantly secondary malignancies. 41,42 Consequently, the establishment of a comprehensive long-term survivorship program screening and assessing these patients for the potential sequelae of prior GCT treatment has been shown to be advantageous and something that should be recommended and offered. 41…”

Section: Surveillance Formentioning

confidence: 99%

Diagnosis and Treatment of Early-Stage Testicular Cancer: AUA Guideline Amendment 2023

Stephenson,

Bass,

Bixler

et al. 2024

Journal of Urology

View full text Add to dashboard Cite

Purpose:The purpose of this American Urological Association (AUA) guideline amendment is to provide a useful reference on the effective evidence-based treatment strategies for early-stage testicular cancer.Methodology/Methods:The original methodology protocol included searches of PubMed®, Embase®, and the Cochrane Central Register of Controlled Trials (CENTRAL) from January 1980 through August 2018. The search strategy used medical subject heading (MeSH) terms and key words relevant to the diagnosis and treatment of early-stage testicular cancer. The searches conducted for the update presented herein utilized the same methodological protocol to capture literature published through March 2023. When sufficient evidence existed, the body of evidence was assigned a strength rating of A (high), B (moderate), or C (low) for support of Strong, Moderate, or Conditional Recommendations. In the absence of sufficient evidence, additional information is provided as Clinical Principles and Expert Opinions.Results:Updates were made to statements on imaging, seminoma management, non-seminoma management, surveillance for stage I testicular cancer, and additional survivorship. Further revisions were made to the methodology and reference sections as appropriate.Conclusions:This guideline seeks to improve clinicians’ ability to evaluate and treat patients with early-stage testicular cancer based on currently available evidence. Future studies will be essential to further support or refine these statements to improve patient care.

show abstract

Section: Surveillance Formentioning

confidence: 99%

Diagnosis and Treatment of Early-Stage Testicular Cancer: AUA Guideline Amendment 2023

Stephenson,

Bass,

Bixler

et al. 2024

Journal of Urology

View full text Add to dashboard Cite

show abstract

“…Cardiovascular toxicities, hearing impairment, peripheral neuropathy, second primary cancers, hypogonadism, infertility, psychological effects, and long-term surgical complications represent some of the multitude of survivorship issues that can occur (Table 4). [134][135][136][137][138][139][140] In addition to underscoring the need for long-term patient follow-up and screening programs for these complications, the late effects also highlight the importance of risk 135 Shrem 2022, 136 Feldman 2018, 137 Kerns 2018, 139 and Agrawal 2020. 140 b lifetime risk for all men diagnosed with GCT) for developing a second, contralateral testicular GCT.…”

Section: Survivorshipmentioning

confidence: 99%

“…Cardiovascular toxicities, hearing impairment, peripheral neuropathy, second primary cancers, hypogonadism, infertility, psychological effects, and long‐term surgical complications represent some of the multitude of survivorship issues that can occur (Table 4). 134–140 In addition to underscoring the need for long‐term patient follow‐up and screening programs for these complications, the late effects also highlight the importance of risk stratification and limiting therapy to just what is needed to achieve a cure and nothing more. The availability of survivorship‐specific resources varies significantly, and many patients, particularly in less well resourced centers, have very limited, if any, access to survivorship services.…”

Section: Survivorshipmentioning

confidence: 99%

See 1 more Smart Citation

Testicular cancer in 2023: Current status and recent progress

McHugh,

Gleeson,

Feldman

2023

CA A Cancer J Clinicians

View full text Add to dashboard Cite

Testicular germ cell tumor (GCT) is the most common solid tumor in adolescent and young adult men. Progress in the management of GCT has been made in the last 50 years, with a substantial improvement in cure rates for advanced disease, from 25% in the 1970s to nearly 80%. However, relapsed or platinum‐refractory disease occurs in a proportion, 20% of whom will die from disease progression. This article reviews the current evidence‐based treatments for extracranial GCT, the acute and chronic toxic effects that may result, and highlights contemporary advances and progress in the field.

show abstract

“…However, these two studies reported only recurrence-free survival, other studies have shown that even for CS1B NSGCT, CSS is >99% regardless of if BEP was given upfront [9,13,35]. While BEP is safe in the short-term, the long-term effects are well known and include cardiovascular disease, secondary malignancies, infertility, hypogonadism, as well as nephro-, neuro-and ototoxicity [46,47].…”

Section: Follow Up In Nsgctmentioning

confidence: 99%

Guideline of guidelines: follow‐up after orchidectomy for clinical stage 1 testicular cancer

2023

Self Cite

View full text Add to dashboard Cite

Several medical organisations have developed evidence‐based guidelines for the diagnosis, management, and follow‐up of testicular cancer. This article aimed to review, compare, and summarise the most updated international guidelines and surveillance protocols for clinical stage 1 (CS1) testicular cancer. We reviewed a total of 46 articles on proposed follow‐up strategies for testicular cancer, and six clinical practice guidelines including four guidelines published by urological scientific associations and two guidelines published by medical oncology associations. Most of these guidelines have been developed by panels of experts with different backgrounds in clinical training, and geographic practise patterns, which explains the considerable variability between published schedules, and recommended follow‐up intensity. We present you with a comprehensive review of the most important clinical practice guidelines and propose unifying recommendations based on the most up to date evidence to help standardise follow‐up schedules based on patterns and risk of disease relapse.

show abstract

Testicular cancer survivorship: Long-term toxicity and management

Cited by 12 publications

References 176 publications

Diagnosis and Treatment of Early-Stage Testicular Cancer: AUA Guideline Amendment 2023

Diagnosis and Treatment of Early-Stage Testicular Cancer: AUA Guideline Amendment 2023

Testicular cancer in 2023: Current status and recent progress

Guideline of guidelines: follow‐up after orchidectomy for clinical stage 1 testicular cancer

Contact Info

Product

Resources

About